SciELO - Scientific Electronic Library Online

 
vol.62 issue3Correlation of the family dinamic score between fathers and mothers of preschool children attending the integral development of the family system (DIF) of Guadalajara, Jalisco (Mexico) author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Boletín médico del Hospital Infantil de México

Print version ISSN 1665-1146

Abstract

RESENDIZ-APARICIO, Juan Carlos et al. Multicentric study, to assess efficacy and security of controlled release OROS methylphenidate in children with attention deficit hyperactivity disorders. Bol. Med. Hosp. Infant. Mex. [online]. 2005, vol.62, n.3, pp.168-176. ISSN 1665-1146.

Introduction. Objective: to assess the efficacy of controlled release OROS MPH (Concerta®) in children with attention deficit/hyperactivity disorder (ADHD) previously treated with immediate release methylphenidate (MPH IR). Material and methods. Children with ADHD, all subtypes, ages 6 to 12 years, with good response to MPH, were switched from IR MPH to OROS MPH once a day (qd in the morning) at 18 to 54 mg/day in a 1 year follow-up trial.The primary end-points for analysis were the last available patient visit using last observation carried forward.The scales used were CGI,Yale's for tics, somatometry, appetite and sleep evaluation from parents, and adverse events record. Results.We included 97 patients, 26 drop-outs [4 (4%) for treatment failure and 2 (2%) hyporexia and cramps]. Of the 71 patients, 64 (90%) male and 7 (10%) female, mean age 9 + 2 years, initial mean weigth 33.8 + 9.7 kg and final 34.7 + 9.9 kg (normal growth). Children with OROS MPH showed significantly greater reductions in core ADHD symptoms. On the basis of mean teacher and parents Iowa Conners and Peers interactions ratings were a significant improvement (P =0.001, Student t). CGI ratings were improvement as well.The most common adverse events were headache (7%) and hyporexia (6%) mild and transient. Conclusion. For the treatment of core ADHD symptoms, OROS MPH dosed qd were well tolerated and efficacy treatment and there were no negative impact on sleep and appetite.

Keywords : Attention deficit hyperactivity disorder; co-morbid disorders; methylphenidate; OROS.

        · abstract in Spanish     · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License